• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Australia OKs sales of Norwood epikeratome

Article

Victoria, Australia—Norwood Devices has received Australia's Therapeutic Goods Administration approval to sell its Centurion SES epikeratome. The device won FDA and CE approval in 2004.

Victoria, Australia-Norwood Devices has received Australia's Therapeutic Goods Administration approval to sell its Centurion SES epikeratome. The device won FDA and CE approval in 2004.

Richard Walmsley, chief executive officer of Norwood Devices, said the potential market in Australia is "significant." However, he sees the single-use disposable separator as the "real revenue and profit generator."

The company expects revenues of $14 million Australian ($10.8 million U.S.) in the 2005 calendar year.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.